Loading...
Market
Will PTC Therapeutics' AADC gene therapy reach $100 million in sales by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
PTC Therapeutics' financial reports and press releases
Story
FDA Approves PTC Therapeutics' Gene Therapy for AADC Deficiency
Nov 13, 2024, 11:18 PM
The U.S. Food and Drug Administration (FDA) has approved PTC Therapeutics' gene therapy for Aromatic L-Amino Acid Decarboxylase (AADC) deficiency, a potentially fatal enzyme deficiency disorder. This therapy is administered directly in the brain, marking a significant advancement in the treatment of neurological conditions. The approval has positively impacted PTC Therapeutics' stock, which saw a 2% increase in aftermarket trading.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Positive • 33%
Neutral • 33%
Negative • 34%
Below $500M • 33%
$500M - $1B • 33%
Above $1B • 34%
Yes • 33%
No • 34%
Top 3 but not best-selling • 33%